Phase I small molecule clinical trial share vs Novel active substance launches
In 2025, phase I small molecule clinical trial share worldwide was 62%; novel active substance launches was 79.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time in 2025 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Phase I small molecule clinical trial share
Unit: % · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 62% |
Novel active substance launches
Unit: count · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 79 |
Shared periods
Side by side
Only one period is published for both series. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Phase I small molecule clinical trial share
Percentage of Phase I clinical trial starts that evaluate small molecule drugs.
3 observations in Global · source organisations: IQVIA
Novel active substance launches
Total number of novel active substances launched.
2 observations in Global · source organisations: IFPMA, IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring